Valuation: KalVista Pharma

Market Cap 1.44B 1.28B 1.19B 1.09B 2.05B 138B 2.06B 14.44B 5.62B 70.66B 5.4B 5.28B 227B P/E 2024
-2.46x
P/E 2025 -5.3x
Enterprise Value 1.42B 1.27B 1.18B 1.08B 2.02B 137B 2.04B 14.28B 5.55B 69.87B 5.34B 5.22B 225B EV / Sales 2024
-
EV / Sales 2025 10.9x
Free-Float
-
Yield 2024 *
-
Yield 2025 -
Manager TitleAgeSince
Chief Tech/Sci/R&D Officer 66 2016-10-31
Chief Executive Officer 61 2024-03-05
President - 2026-06-10
Director TitleAgeSince
Chairman - 2026-06-10

Financials

2024 2025
Net sales - 73.62M 65.67M 61.18M 55.68M 105M 7.09B 106M 739M 288M 3.62B 276M 270M 11.63B
Net income -127M -113M -105M -95.79M -180M -12.2B -182M -1.27B -495M -6.23B -475M -465M -20.01B -164M -147M -137M -124M -234M -15.82B -236M -1.65B -642M -8.08B -617M -603M -25.96B
Net Debt -203M -181M -169M -154M -289M -19.56B -291M -2.04B -793M -9.98B -762M -746M -32.09B -16.01M -14.28M -13.3M -12.11M -22.8M -1.54B -22.97M -161M -62.54M -787M -60.09M -58.79M -2.53B
Logo KalVista Pharma
KalVista Pharmaceuticals, Inc. is a global pharmaceutical company. It has discovered and developed EKTERLY, an oral on-demand treatment for hereditary angioedema (HAE). EKTERLY is formulated as a film-coated tablet for oral administration, with high bioavailability and selectivity for plasma kallikrein, enabling maximal dosing and a rapid decline in edema effectors that cause swelling during an HAE attack. Its clinical trials include KONFIDENT-KID, KONFIDENT-S and KONFIDENT. KONFIDENT-KID is an open-label clinical trial of sebetralstat for on-demand treatment of HAE attacks in pediatric patients. KONFIDENT-KID collects safety, pharmacokinetic and efficacy data for each patient for up to one year and features a proprietary pediatric orally disintegrating tablet formulation of sebetralstat. KONFIDENT-S study is an open-label extension trial to evaluate the long-term safety of sebetralstat for on-demand treatment of HAE attacks in adolescent and adult patients with type I or type II HAE.
Employees
275
Sector
-
Trader
-
Investor
-
Global
-
Quality
-
ESG MSCI
A